Kornimate/medical-research-clean huggingface dataset:
working on asymmetry in parkinson's disease

Conditions: Parkinson's Disease

Summary: freezing of gait (fog) is a disabling episodic gait disturbance that is common among patients with parkinson's disease (pd). the symptoms of pd generally show an asymmetric onset and progression. in particular, impairments in rhythmicity, symmetry, and bilateral coordination have been reported to be associated with fog episodes. as the maintenance of gait depends on the precise alternating movements of both legs, irregularities in rhythm, symmetry, and bilateral coordination may impair gait sequence, potentially causing freezing. results of recent studies strongly suggest that bilateral uncoordinated gait and marked gait asymmetry are associated with fog. moreover, it has recently been hypothesized that this may lead to a degree of asymmetric motor function, and that fog in parkinsonian patients is triggered by a breakdown in the bilateral co-ordination underlying the normal timing of gait. aim of the study was to evaluate how the modulation of asymmetry through physical therapy might improve gait and fog.

the patients will be'blind' to the study protocol and will be randomly assigned to one of the three study arms: 1) physiotherapy aimed to potentiate the more affected body side (worst side improvement, wsi); 2) physiotherapy aimed to potentiate the less affected body side (best side improvement, bsi); 3) physiotherapy aimed to potentiate both sides equally (standard treatment, st). each group will be undergo physiotherapy twice a week for three months. each session will have duration of one hour and include a first part of warming up, a final part of cooling down (these two parts are the same for all the groups) and an active part (which is different from group to group). the active part includes exercises which are alike for all the groups but with a number of repetitions different from group to group according to the aim of potentiating the most affected side (wsi) or the least affected side (bsi) or both sides equally (in this case the number of repetitions was the same for both sides; st). medical treatment will be kept stable through all the study duration; medications are expressed as levodopa daily dose equivalent (ledd).

Eligibility criteria:
inclusion criteria: * parkinson's disease, freezing of gait history, informed consent exclusion criteria: * depression, severe orthopedic diseases

Keywords: parkinson's disease freezing of gait asymmetry rehabilitation physical therapy
reducing dose and irradiated volume in cervical prophylactic irradiation for nasopharyngeal cancer

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to investigate whether reducing both the dose and the irradiated volume of cervical prophylactic irradiation in patients with nasopharyngeal cancer can maintain efficacy while decreasing toxicity. this will be achieved through a comparison of standard cervical prophylactic irradiation with a reduced-dose and reduced-volume approach.

patients with non-metastatic nasopharyngeal cancer who are candidates for receiving definitive imrt are randomly assigned to receive either standard cervical prophylactic irradiation or a reduced-dose and reduced-volume approach. the standard arm receives the conventional dose and volume of irradiation, while the experimental arm receives a lower dose and a smaller irradiated volume. both groups will undergo intensity-modulated radiotherapy (imrt) to the primary tumor and involved lymph nodes. the primary endpoint of this study is regional-control (rc), and secondary endpoints include overall survival (os), local control (lc), distant metastasis-free survival (dmfs), and toxicity. all efficacy analyses will be conducted in the intention-to-treat population, and the safety population will include only patients who receive their randomly assigned treatment.

Eligibility criteria:
inclusion criteria: 1. pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma; 2. no distant metastatic; 3. patients with baseline mri date of nasopharynx and neck, and completed the first course of treatment in our hospital; 4. eastern cooperative oncology group (ecog) score of 0 or 1; 5. signing informed consent; 6. follow up regularly and comply with test requirements. exclusion criteria: 1. disease progression during imrt; 2. previous malignancy or other concomitant malignant diseases; 3. the evaluation information of tumor efficacy can not be obtained; 4. receive blind treatment in other clinical research; 5. have or are suffering from other malignant tumors within 5 years (except non- melanoma skin cancer or pre-invasive cervical cancer); 6. serious complications, such as uncontrolled hypertension, coronary heart disease, diabetes, heart failure, etc; 7. active systemic infection; 8. no or limited capacity for civil conduct; 9. the patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study; 10. pregnancy or lactation period;
evaluation of well-being interventions in adults with tbi

Conditions: TBI (Traumatic Brain Injury)

Summary: the purpose of this research is to evaluate the potential benefits of two intervention programs in adults with tbi to improve well-being and other outcomes that are maintained over time.

the current study will examine the efficacy of signature strengths in adults with tbi to improve self-concept and other outcomes that are maintained over time. preliminary evidence suggests that after a tbi, an individual can experience significant alteration to their personal identity and a perceived loss of their pre-injury self. by using this signature strength intervention, adults with moderate to severe tbi will be able to become aware of their most used "signature" strengths, explore how these strengths are used in everyday life, and apply them in future situations to bring well-being and to better cope with stressors.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * have a diagnosis with moderate to severe tbi * at least one year post injury * able to speak and read english fluently exclusion criteria: * have a history of multiple sclerosis, stroke, seizures or another nervous system injuries disease in the past (like brain tumor or epilepsy) * have a significant psychiatric illness (like, schizophrenia or psychosis) * currently taking steroids and/or benzodiazepines as determined by study staff review of medications * significant alcohol or drug abuse history (requiring inpatient treatment) * history of stroke, schizoaffective disorder, bipolar disorder, personality disorder or severe depression determined by extensive screening by a trained staff member * previous participation in a signature strengths program

Keywords: tbi, traumatic brain injury, traumatic injury, brain injury
plasma total antioxidant status and thiobarbituric acid-reacting substances in patients with inguinal hernia

Conditions: Inguinal Hernia

Summary: introduction: any form of trauma, including surgery is known to result in oxidative stress. single incision laparoscopy is a step forward towards almost scarless surgery. it is also expected to result in a lower degree of free radicals generation and faster normalization of the organism's antioxidant capacity. aim: the aim of the study was to assess a number of plasma oxidative stress markers in patients operated due to inguinal hernia using typical totally extra peritoneal (tep) and modified single incision laparoscopic surgery (sils) methods. material and methods: thirty-two consecutive patients with no acute disease and severe chronic disorder, were qualified for inguinal hernia laparoscopic surgery. all were caucasian males, aged 24-69 and they underwent one of two surgical approaches: totally extra-peritoneal repair (tep) and single incision laparoscopic surgery (sils). tep patients created group 1 (n= 17) and sils patients formed group 2 (n= 17). total antioxidant status (tas) and thiobarbituric acid-reacting substances (tbars) were determined in three time points: before, one day and four days after the laparoscopic surgery.

thirty-two consecutive patients with no acute disease and severe chronic disorder were qualified for inguinal hernia laparoscopic surgery. all were caucasian males, aged 24-69 underwent one of two different surgical approaches: totally extra-peritoneal (tep) repair and single incision laparoscopic surgery (sils). tep patients created group 1 (n= 17) and sils patients formed group 2 (n= 17). blood sampling and biochemical analysis ulnar venous blood samples were collected from the participants three times (fasting, between 6:00 and 7:00 am): before (0), one day (1) and four days (2) after laparoscopic surgery. baseline (0) blood samples were used for routine pre-operative laboratory assessment, including complete blood count, basic coagulation tests, c-reactive protein, glucose and electrolytes levels. total antioxidant status (tas) and thiobarbituric acid-reacting substances (tbars) were determined in three time points: 0, 1 and 2 as described above. spectrophotometry was used to measure tas (randox laboratories, crumlin, antrim, uk) on statfax 1904plus (awareness technology, palm city, fl) and tbars according to the okhawa method \[11\] (sigma reagents, germany) on specord m40 (carl-zeiss, germany). the intra- and inter-assay coefficients of variation were as follows: tas (1.6 % and 3.7%), and tbars (1.9% and 3.8%)

Eligibility criteria:
inclusion criteria: * patients with inguinal hernia. exclusion criteria: * patients with acute disease and severe chronic disorder.

Keywords: inguinal hernia repair totally extraperitoneal (tep) single incision laparoscopic surgery (sils) plasma total antioxidant status
treatment of tuberculosis multidrug resistance treatment of tuberculosis multidrug resistance

Conditions: Multi-drug Resistant Tuberculosis

Summary: the principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.

study participants will be followed up, under existing protocol derived from a study protocol developed by the "union internationale contre les maladies respiratoires" and carried out already in 9 africans countries. participants will be hospitalised for at least four month, period which they will be given treatments, assessed for adverse events, monitored for tb-mr strains using culture techniques, at the monthly basis. if patients found with negative sputum culture at month four they will be dischrged from the hospital, and then treated four an additional five montns and then follow up, clinically and biologically for an additional six months before being declared as cured.

Eligibility criteria:
inclusion criteria: * aged 15 years and above * never been treated with second line anti-tb drugs for more than one month, * give written consent to participate * agree to be hospitalised for at least four months in specialised healthcare * willing to adhere to ambulatory directly observed treatment by a healthcare worker; exclusion criteria: * pregnant during inclusion process * presented with altered clinical status condition as judged by the clinician * knowing of history of hypersensitivity reaction to any of the drugs to be used * baseline ecg does not show a qt space superior to 500ms * refusal to participate into study.

Keywords: multi-drug resistant tuberculosis short course regimen protocol
observational study to assess safety of h1n1 pandemic influenza vaccine

Conditions: Influenza; Pandemic Influenza

Summary: the purpose of this observational study, which will be initiated as soon as the licensed h1n1 pandemic influenza vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse events in all vaccinated subjects.


Eligibility criteria:
inclusion criteria: male and female subjects, per indication on license or per official vaccine recommendations, will be eligible for participation in this study if: * they will be administered celvapan (= baxter´s h1n1 pandemic influenza vaccine) * they are 2 months of age or older at the time of first vaccine administration * their medical history is available * the investigator believes they will comply with the foreseen vaccination schedule and will reliably observe signs or symptoms of adverse events during the observational period * they and/or their parent(s)/legal guardian(s) provide written informed consent, and assent where appropriate, prior to study entry according to national law exclusion criteria: male and female subjects will be excluded from participation in this study if: * they have already been administered another h1n1 pandemic vaccine * they have any contraindication to vaccination (as per the summary of product characteristics and/or relevant national immunization guidelines)
analyzing the impact of occlusal reduction on the pain following root canal therapy in molar teeth with and without pain in turkish patients.

Conditions: Irriversible Pulpitis

Summary: introduction: this study aimed to compare the intensity of postoperative pain after single-visit root canal treatment of symptomatic or asymptomatic teeth following occlusal reduction. methods: a total of 140 symptomatic or asymptomatic patients in need of root canal therapy were registered in this prospective, single-center, single-blind, randomized clinical trial. for all patients, root canal treatment was carried out in a single visit, and the teeth were restored using composite resin. the teeth were randomly allocated into two equal groups according to whether occlusal reduction was done or not. the patients' pain were assessed using a 0-3 verbal rate scale 1, 3, and 7 days following root canal treatment. the pain incidence and intensity were compared using the chi-square and fisher's exact tests.

root canal treatments is usually associated with post-operative pain and this is a bothersome situation for both patient and practitioner. due to this reason number of researches focus on the factors that may relief patients pain. occlusal reduction is one of the factors that means the chewing surface of the teeth are cut off and no longer in contact.despite the large number of studies on this subject, no consensus has been reached. decoupling group standardization and arriving at a more consistent conclusion were the goals of this research. the aim of this research is to evaluate the impact of occlusal reduction on postoperative pain in both symptomatic and asymptomatic molar teeth.

Eligibility criteria:
inclusion criteria: * healty patients * maxillary and mandibulary first and second molars * irriversible pulpitis cases with or without prior discomfort exclusion criteria: * patients under 18 years old, * patients older 65 years old, * teeth with previously undergone root canal treatment, * complicating systemic diseases, * allergies o local anesthetic agents, * presence of acute apical apsesses, * history of trauma, * analgesic, antibiotic or antiinflamatory intake 7 days before treatment, * periodontal pockets deeper than 4 mm, * multiple teeth that require endodontic treatment, * pregnancy, * teeth that can not be restored, * patients who needed emergency treatment, * grade 2 or 3 mobility, * patients with bruxism

Keywords: analgesics occlusal reduction postoperative pain single-visit endodontic treatment
center for stroke research berlin (csb) prospective stroke cohort

Conditions: Stroke

Summary: the primary aim of the study is to derive and validate risk scores for vascular endpoints (recurrent stroke, myocardial infarction, and other complications of stroke) and for death following an incident stroke. for this purpose patients with an incident stroke will be followed for 36 months with additional assessments at 12, 24 and 36 months.

risk of vascular disease including stroke, myocardial infarction, and vascular death is high after stroke but there are only few prognostic models for long term risk up to 3 years. about 850 patients with an incident stroke will be followed for 3 years with assessments at baseline and at 3, 12, 24, and 36 months. factors that have already been reported to be significant predictors of vascular diseases in previous studies as well as new biomarkers (e.g. neuroimaging, blood based biomarkers) identified in this cohort will be considered. the improvement of discrimination including these new variables in the models will be investigated. several measures of improving predictive properties (e.g. calibration, discrimination, net reclassification) will be used to compare predictive models with different complexity. the model will be validated using the bootstrap method (internal validation) and an independent external sample in cooperation with the institute for stroke and dementia research, munich.

Eligibility criteria:
inclusion criteria: * age ≥18 years * language: german * first ever stroke including ischemic stroke, primary intracranial hemorrhage and cerebral venous sinus thrombosis that occurred with stroke onset in the last 7 days * written informed consent by patient prior to study participation * willingness to participate in follow-up exclusion criteria: * prior stroke (definition according to who definition) * patients presenting brain tumour or brain metastasis * participation in an intervention- / amg-study

Keywords: first ever stroke
phase 1/2 study of khk7580 for secondary hyperparathyroidism in patients receiving hemodialysis

Conditions: Hyperparathyroidism

Summary: this study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single and multiple administration of khk7580 for secondary hyperparathyroidism in patients receiving hemodialysis


Eligibility criteria:
inclusion criteria: * written informed consent * stable chronic renal disease patients receiving hemodialysis 3 times weekly for at least 12 weeks prior to the screening * intact pth value ≥ 240 pg/ml at the screening * corrected serum calcium ≥ 8.4 mg/dl at the screening exclusion criteria: * patients with primary hyperparathyroidism * patients who received cinacalcet within 2 weeks prior to the screening * patients with change in dose or dosing regimen of active vitamin d/ its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening * patients who received parathyroidectomy and/or parathyroid intervention * patients with uncontrolled hypertension and/or diabetes * patients with severe heart disorder * patients with severe hepatic disease * patients who take investigational drug in other clinical trial within 12 weeks prior to the screening * patients who have been judged ineligible to participate in the study by the investigator

Keywords: patients receiving hemodialysis secondary
evaluation of binocular visual acuity and refractive stability in the alcon clareon intraocular lens

Conditions: Cataract

Summary: the objective is to evaluate refractive stability (spherical equivalent change ≤ 0.50d from 1-month to 3-months).

this study is a single-arm, evaluator masked clinical evaluation study of refractive stability, after successful bilateral cataract surgery. subjects will be assessed pre-operatively, operatively and at 1 month and 3 months post-operatively. clinical evaluations will include measurement of bilateral visual acuity, manifest refraction, and defocus curve.

Eligibility criteria:
inclusion criteria: subjects are eligible for the study if they meet the following criteria: note: ocular criteria must be met in both eyes. * presenting for uncomplicated bilateral cataract surgery and have an interest in an iol option * gender: males and females. * age: 50 or older * willing and able to provide written informed consent for participation in the study * willing and able to comply with scheduled visits and other study procedures. * have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error and cataract) * potential postoperative visual acuity of (20/25 snellen) or better in both eyes exclusion criteria: if any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * irregular astigmatism (e.g. keratoconus) * corneal pathology (e.g. scar, dystrophy, pterygium, severe dry eye) * previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g. corneal transplant, dsaek, lamellar keratoplasty) * previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy) * diabetic retinopathy * macular pathology (e.g. armd, erm) * history of retinal detachment * any patient based on barrett toric calculator that will have ≥ 0.75d residual astigmatism if clareon® non-toric iol is implanted * subjects who have an acute or chronic disease or illness that would confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness), that are known to affect postoperative visual acuity * participation in any investigational drug or device trial within the previous 30 days prior to the start date of this trial (or currently participating) the principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial. pregnancy has a known effect on the stability of refractions and visual acuity. as such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Keywords: monofocal iol clareon